Osteogenesis Imperfecta (OI)

DBCOND0113457Congenital, Hereditary, and Neonatal Diseases and AbnormalitiesImmune System Diseases

Osteogenesis Imperfecta (OI) is the indication for 4 drugs in DrugBank. It is covered by 4 curated, structured indications.

Also known as
Osteogenesis Imperfecta · Brittle Bone Disease · Osteogenesis Imperfecta, Type I
Classified under
Indicated drugs

Resolves to

Vocabularies
MeSHM0015534ICD-10Q78.0SNOMED CT157008000MedDRA10006371UMLSC0023931

What you can answer from here — as of October 22, 2026

4Indicated drugsWith each drug's targets and mechanism
Listed above
4Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
47Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Drug reporting it as an adverse effectWith incidence where the label states it
Sign in

Which approved drugs for Osteogenesis Imperfecta (OI) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In